AVIR
Price
$3.09
Change
-$0.05 (-1.59%)
Updated
Feb 21 closing price
Capitalization
260.99M
9 days until earnings call
CDXS
Price
$4.18
Change
-$0.08 (-1.88%)
Updated
Feb 21 closing price
Capitalization
339.75M
3 days until earnings call
Ad is loading...

AVIR vs CDXS

Header iconAVIR vs CDXS Comparison
Open Charts AVIR vs CDXSBanner chart's image
Atea Pharmaceuticals
Price$3.09
Change-$0.05 (-1.59%)
Volume$309.14K
Capitalization260.99M
Codexis
Price$4.18
Change-$0.08 (-1.88%)
Volume$676.07K
Capitalization339.75M
AVIR vs CDXS Comparison Chart
Loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVIR vs. CDXS commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Hold and CDXS is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (AVIR: $3.10 vs. CDXS: $4.39)
Brand notoriety: AVIR and CDXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVIR: 69% vs. CDXS: 67%
Market capitalization -- AVIR: $260.99M vs. CDXS: $339.75M
AVIR [@Biotechnology] is valued at $260.99M. CDXS’s [@Biotechnology] market capitalization is $339.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVIR’s FA Score shows that 0 FA rating(s) are green whileCDXS’s FA Score has 0 green FA rating(s).

  • AVIR’s FA Score: 0 green, 5 red.
  • CDXS’s FA Score: 0 green, 5 red.
According to our system of comparison, CDXS is a better buy in the long-term than AVIR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVIR’s TA Score shows that 4 TA indicator(s) are bullish while CDXS’s TA Score has 4 bullish TA indicator(s).

  • AVIR’s TA Score: 4 bullish, 4 bearish.
  • CDXS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both AVIR and CDXS are a good buy in the short-term.

Price Growth

AVIR (@Biotechnology) experienced а +3.68% price change this week, while CDXS (@Biotechnology) price change was +6.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +3.99%, and the average quarterly price growth was +2.35%.

Reported Earning Dates

AVIR is expected to report earnings on May 07, 2025.

CDXS is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (+4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDXS($340M) has a higher market cap than AVIR($261M). AVIR YTD gains are higher at: -7.463 vs. CDXS (-7.966). CDXS has higher annual earnings (EBITDA): -30.09M vs. AVIR (-200.08M). AVIR has more cash in the bank: 483M vs. CDXS (90.3M). AVIR has less debt than CDXS: AVIR (1.84M) vs CDXS (41.8M). CDXS has higher revenues than AVIR: CDXS (64.4M) vs AVIR (0).
AVIRCDXSAVIR / CDXS
Capitalization261M340M77%
EBITDA-200.08M-30.09M665%
Gain YTD-7.463-7.96694%
P/E RatioN/AN/A-
Revenue064.4M-
Total Cash483M90.3M535%
Total Debt1.84M41.8M4%
FUNDAMENTALS RATINGS
AVIR vs CDXS: Fundamental Ratings
AVIR
CDXS
OUTLOOK RATING
1..100
5860
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
98100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
7846
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVIR's Valuation (43) in the Biotechnology industry is in the same range as CDXS (53) in the Chemicals Specialty industry. This means that AVIR’s stock grew similarly to CDXS’s over the last 12 months.

AVIR's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that AVIR’s stock grew similarly to CDXS’s over the last 12 months.

AVIR's SMR Rating (96) in the Biotechnology industry is in the same range as CDXS (98) in the Chemicals Specialty industry. This means that AVIR’s stock grew similarly to CDXS’s over the last 12 months.

CDXS's Price Growth Rating (46) in the Chemicals Specialty industry is in the same range as AVIR (78) in the Biotechnology industry. This means that CDXS’s stock grew similarly to AVIR’s over the last 12 months.

AVIR's P/E Growth Rating (95) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that AVIR’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVIRCDXS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 6 days ago
72%
Bullish Trend 6 days ago
90%
Momentum
ODDS (%)
Bullish Trend 6 days ago
72%
Bullish Trend 6 days ago
87%
MACD
ODDS (%)
Bullish Trend 6 days ago
59%
N/A
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
76%
Bullish Trend 6 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
82%
Bearish Trend 6 days ago
81%
Advances
ODDS (%)
Bullish Trend 19 days ago
78%
Bullish Trend 6 days ago
85%
Declines
ODDS (%)
Bearish Trend 17 days ago
80%
Bearish Trend 13 days ago
84%
BollingerBands
ODDS (%)
N/A
Bullish Trend 6 days ago
90%
Aroon
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 6 days ago
83%
View a ticker or compare two or three
Ad is loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

AVIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with MGTX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVIR
1D Price
Change %
AVIR100%
-1.59%
MGTX - AVIR
48%
Loosely correlated
+1.27%
HEPA - AVIR
47%
Loosely correlated
-1.58%
DNLI - AVIR
45%
Loosely correlated
+1.97%
RCKT - AVIR
45%
Loosely correlated
+3.15%
TSVT - AVIR
44%
Loosely correlated
-5.91%
More

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+1.86%
DNLI - CDXS
50%
Loosely correlated
+1.97%
BEAM - CDXS
45%
Loosely correlated
+3.36%
DNA - CDXS
43%
Loosely correlated
-6.52%
SCPH - CDXS
42%
Loosely correlated
-1.09%
AVIR - CDXS
42%
Loosely correlated
-1.59%
More